Sign In
Buy JAGX
$2.92
-0.300 (-9.32%)
At Close: Jun 03, 2026
Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestin
3 Obstacles Investors Face When Buying Penny Stocks
06:37am, Tuesday, 23'rd Apr 2024
Penny stocks represent a unique opportunity for investors aiming to expand their portfolios without a significant initial investment. Trading penny stocks can yield high returns due to their low purch
Jaguar planning to begin commercial launch of FDA-approved Gelclair® prescription gel for oral mucositis (also called “chemo mouth”) in Q3 2024 Company to feature “ Make Cancer Less Shitty ”
Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and d
Why Is Jaguar Health (JAGX) Stock Up 44% Today?
11:34am, Tuesday, 16'th Apr 2024
Jaguar Health (NASDAQ: JAGX ) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new license for a chemo mouth treatment. Jaguar Health is looking to treat chemo mouth,
Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse ev
What Is Going on With Jaguar Health (JAGX) Stock Today?
10:40am, Wednesday, 10'th Apr 2024
Former meme stock Jaguar Health (NASDAQ: JAGX ) has won the approval of certain measures meant to help maintain its Nasdaq listing. These include an extension to Aug. 13 to regain compliance by gettin
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
04:15pm, Tuesday, 09'th Apr 2024
Company not implementing a reverse split at this time Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
08:30am, Monday, 08'th Apr 2024
Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2024 / Jaguar He
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
08:50am, Tuesday, 02'nd Apr 2024
Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S. Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN fo
Jaguar Health, Inc. (JAGX) Q4 2023 Earnings Call Transcript
10:47am, Monday, 01'st Apr 2024
Jaguar Health, Inc. (JAGX) Q4 2023 Earnings Call Transcript
Jaguar Health Reports 2023 Financial Results
08:00am, Monday, 01'st Apr 2024
Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year ended December 31, 2022, a decrease of 18% Net Q4 2023 revenue of approx
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
08:30am, Wednesday, 27'th Mar 2024
Click here to register for April 1 investor webcast Company plans to file its Earnings Report on April 1, 2024 on Form 10-K for the year ended December 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / March
SAN FRANCISCO, CA / ACCESSWIRE / January 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on January 31, 2
Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference
08:30am, Thursday, 30'th Nov 2023
Top line data for Jaguar Health's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy forthcoming SAN FRANCISCO, CA / ACCESSWIR
